In an exploratory retrospective study, treatment with the glycoprotein IIb/IIIa receptor antagonist tirofiban in elderly patients aged 75 years and older with acute ischemic stroke was not associated with a statistically significant increase in bleeding events or mortality in unadjusted comparisons. The single-center investigation, published in BMC Neurology by researchers including Liujie Yin, Hongke Wang, Mingzhe Li, Luchao Jing, and Shize Li, examined whether safety and functional outcomes differed between elderly and younger patients receiving the medication.
Although tirofiban is established as a safe and effective treatment for acute ischemic stroke, clinical evidence defining its safety and therapeutic efficacy in very elderly populations aged 75 and above has remained limited. To address this question, investigators reviewed records from 150 acute ischemic stroke patients treated at Zhengzhou Central Hospital between January 2022 and June 2024. The study cohort was divided into an elderly group comprising 46 patients aged 75 years or older and a non-elderly group comprising 104 patients under 75 years of age.
Baseline characteristics were gathered from both cohorts, and researchers evaluated functional recovery and neurological deficits before treatment, after treatment, at discharge, and at 90 days. The primary efficacy outcome was the change from baseline to 90 days in National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores. Neurological improvement was comparable across cohorts, with no statistically significant differences observed in 90-day score changes. The median change in NIHSS score from baseline to 90 days was 4.0 points in the elderly group versus 3.0 points in the non-elderly group (P = 0.663), while both groups exhibited an identical median change of 1.0 point on the mRS (P = 0.199).
In an exploratory subgroup analysis restricted to patients with an onset-to-treatment time of less than eight hours, both the elderly and non-elderly groups demonstrated similar improvements on NIHSS and mRS metrics at 90 days. Drug safety evaluations assessed comparative mortality and post-medication bleeding complications, which included moderate to severe symptomatic intracranial hemorrhage, asymptomatic intracranial hemorrhage, gum bleeding, skin and mucous membrane bleeding, gastrointestinal bleeding, urinary bleeding, and other bleeding events.
Safety assessments revealed that no deaths occurred in either group during the study. The incidence of any bleeding events was 19.6 percent in the elderly group compared with 9.6 percent in the non-elderly group, a difference that did not reach statistical significance (P = 0.091). However, the authors noted that this numerically higher bleeding rate warrants caution and confirmation in larger studies. The investigators emphasized that due to the retrospective design, small elderly sample size, and unadjusted baseline differences between groups, these findings do not establish equivalence or definitive safety and efficacy, concluding that while age alone should not necessarily preclude tirofiban use, prospective randomized studies with adequate adjustment for confounders are needed.
Subject of Research: Safety and functional outcomes of tirofiban in elderly acute ischemic stroke patients
Article Title: Safety of GPâ…¡b/â…¢a receptor antagonist tirofiban in elderly patients with acute ischemic stroke
Article References: Yin, L., Wang, H., Li, M., Jing, L., & Li, S. (2026). Safety of GPâ…¡b/â…¢a receptor antagonist tirofiban in elderly patients with acute ischemic stroke. BMC Neurology. https://doi.org/10.1186/s12883-026-05545-6
Image Credits: AI Generated
DOI: 10.1186/s12883-026-05545-6
Keywords: tirofiban, acute ischemic stroke, elderly patients, stroke treatment, bleeding risk, neurology, NIHSS, modified Rankin Scale, Safety, receptor, antagonist, elderly
News Source: Cassandra Pierce. (November 7, 2026). Study Evaluates Tirofiban Safety in Elderly Acute Ischemic Stroke Patients. Scienmag.



